2 stories mentioning GOSSUpdated just now
Every FINWIRES story that references GOSS, newest first.
Gossamer Bio (GOSS) has an average rating of overweight and mean price target of $3.86, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)
(Updates with the stock move in the headline and the first two paragraphs.)Gossamer Bio's (GOSS) shares surged more than 30% in Tuesday's pre-market activity after the company said it is proceeding toward a September new drug application submission for seralutinib as a potential treatment for patients with pulmonary arterial hypertension.The plans follow a "productive" pre-application meeting with the U.S. Food and Drug Administration, the company said Monday, when shares closed almost 47% higher in regular trading.Gossamer has also reacquired worldwide development and commercial rights to seralutinib from Chiesi, eliminating a previous 50/50 profit share deal and requiring Chiesi to make a one-time $5 million payment, it said.Its shareholders have also approved proposals related to a convertible note exchange and authorized it to effect a reverse stock split, to take effect after Q3 2026, the company said.The company also reported that cash, cash equivalents and marketable securities totaled approximately $57 million as of June 30.Price: $0.26, Change: $+0.062, Percent Change: +30.39%
